Interim report
Page 1
1 ODI Pharma Schweiz AG Grafenauweg 8 6301 Zug Switzerland ODI Pharma AB Östermalmstorg 1 114 42 Stockholm Sweden ODI Pharma Sp. z o.o. Towarowa 28 00-839 Warschau Poland HALF-YEAR REPORT July 2025 – December 2025
Page 2
2 ODI PHARMA HALF-YEAR REPORT In this half-year report, the following definitions apply, unless stated otherwise: The “Company” or “ODI Pharma” refers to ODI Pharma AB with org. number (Swedish corporate registration number) 559223-1392. Amount in brackets refers to the corresponding period in the previous year. ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018 when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o. Second quarter (202 5-10-01 – 202 5-12-31) • The Group's net sales amounted to SEK 10,932,119 (0). • The Group's profit after financial items amounted to SEK 1,298,597 (-2,562,520). • Result per share amounted to SEK 0.07 (-0.16).* Six months (2025 -07-01 – 2025 -12-31) • The Group's net sales amounted to SEK 16,900,262 (-4,965). • The Group's profit after financial items amounted to SEK 1,255,378 (-3,953,290). • Result per share amounted to SEK 0.07 (-0.25).* • The solidity as of 2025-12-31 was 19% (7%).** * The Company’s result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of December 2025, amounted to 18,348,419 (15,915,034) shares. The result per share based on the average number of shares of 18,348,419 (15,915,034) amounts to SEK 0.07 (-0.10) for the first six months 2025-07-01 to 2025-12-31. ** Solidity: Equity divided by total capital.
Page 3
3 Highlights during the second quarter • ODI Pharma AB announced a reverse profit warning following significantly stronger revenue development in Q2 2025/2026 (October–December 2025), with preliminary unaudited revenues of approximately SEK 11 million, corresponding to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial improvement compared to the corresponding quarter of the previous fiscal year, when revenues amounted to SEK 0. Highlights after the end of the period • ODI Pharma repaid EUR 100,000 in outstanding debt, corresponding to approximately SEK 1.1 million, strengthening the Company’s financial position and reducing leverage.
Page 4
4 MESSAGE FROM THE CHAIRMAN, VOLKER WIEDERRICH ODI Pharma delivers a very strong second quarter, clearly reflecting the operational and commercial progress achieved over the past year. Revenue increased by approximately 83 percent compared to the previous quarter, amounting to approximately SEK 11 million in Q2 2025/2026. This development marks a decisive step forward for the Company and demonstrates that the measures implemented in recent quarters are generating tangible financial results. For the quarter, ODI reports a positive net result. The return to profitability confirms the scalability of our partner-led and capital-efficient business model. Increased order volumes during Q2, with additional deliveries scheduled for Q3, further underline the growing demand for our product portfolio and provide continued commercial momentum. The development seen during Q2 is not considered temporary but reflects the current level of activity in the business. Our business has become significantly more solid compared to earlier periods. Operational stability, improved logistics, and stronger commercial execution have materially strengthened our financial position. ODI has also consolidated its role as a key participant in the Eastern European market. We have substantially exceeded our previous ambition of reaching a 10 percent market share and now operate as a major player in the region. The Company has demonstrated strong growth over the past year, and we continue to assess further expansion opportunities, both strategically and geographically, within regulated European medical cannabis markets. Our focus remains on disciplined execution, sustainable growth, and long-term value creation. I would like to thank our investors for their continued confidence in the Company. Their support has been instrumental in strengthening ODI Pharma’s position and enabling the progress we are delivering. Volker Wiederrich Chairman of the Board, ODI Pharma AB
Page 5
5 ABOUT ODI PHARMA ODI Pharma aims to become a leading supplier of medical cannabis on the Company’s target markets in Europe. The European market for medical cannabis has the potential to become the world’s largest market for medical cannabis. ODI Pharma was founded and is led by a team of professionals with long experience as doctors, researchers, investors, and corporate managers. The founders and board members of the Company have an extensive background in both trading and the medical cannabis industry. ODI Pharma, based on its European network, subsidiaries, and partners, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. Z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. As this goal is coming to fruition, sights are being set for expansion to other markets. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals. The main focus of ODI Pharma is on the medical cannabis products that are sold to clients and patients through ODI Pharma’s relationships with pharmacies via wholesale distributors. In addition, ODI Pharma believes that CBD-infused cosmetics is thought to be a perfect complement to its pharmaceutical focus, allowing ODI Pharma to benefit from synergies and mutual benefits. In August 2023, ODI Pharma successfully expanded its business relationship with the NEUCA group by signing an exclusive supply collaboration agreement covering not only Poland, but 23 countries in Eastern Europe. Further, the Company has a valuable supply contract with a wholly owned subsidiary of the largest cannabis producer in the world. The supplier is a first- tier producer who operates at the highest standards. ODI Pharma believes that European clients require a wide variety of medical cannabis products of high quality to treat specific illnesses. The Company is a producer of finished pharmaceutical cannabis products and therefore has no cultivation operations but has access to a wide variety of different strains, oils, and the latest formulas. The Company intends to provide a range of medical cannabis products.
Page 6
6 The products Medical cannabis comes in a range of different products with different levels of THC (Tetrahydrocannabinol) and CBD (Cannabidiol). The products that ODI Pharma represent for the Polish market, per the Polish Strategy, are products that will be approved by the Polish governmental agencies. Initially, the products will be dried flowers, since this is the product that this far has been regulated in Poland (even though the law in Poland allows for a range of derivates from the cannabis plant). These products are based on the raw material of fully approved cannabis imported by the Company and strategic partners. The dried flowers can be consumed by the patients in various ways following the guidelines of the pharmacists. ODI Pharma is evaluating other product types besides dried flowers to be sold on the Polish market. ODI Pharma intends to be up to date on trends and regulatory requirements and future products may, therefore, differ from the current products. The market demand decides what type of medical cannabis products the Company will supply, which the Company’s flexible business model enables. The production of the products is fully integrated with NEUCA. The current market price of dried flowers in Poland is approx. EUR 10.00-13.00 (based on current exchange rate) per gram, ODI Pharma intends to at least match this price, while still providing high-quality products. Whatever product type of medical cannabis ODI Pharma provides; the objective is to be cost- efficient concerning what has previously been stated.
Page 7
7 Target groups There is a total of about 40+ indications in which medical cannabis may potentially show results in terms of efficacy. The Supreme Pharmaceutical Chamber of Poland (Naczelna Izba Aptekarska) estimates an immediate market demand of 300,000 patients by 2025. Jędrzej Sadowski, the author of the bill legalizing cannabis, estimates 300,000 patients as well. ODI Pharma assumes that it will take some years to reach the potential patients’ number that uses the product and the Company estimates that this will be reached in 2025. The Polish regulations do not limit the prescriptions for medical cannabis concerning certain ailments – therefore all physicians have the authorization to prescribe medical cannabis to all their patients and all types of illnesses. The Supreme Pharmaceutical Chamber of Poland suggested the application with treatable conditions including nausea caused by chemotherapy, epilepsy, symptoms of multiple sclerosis, and chronic pain.
Page 8
8 ABOUT THE HALF -YEAR REPORT Group structure ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG (100 %). ODI Pharma Schweiz AG has an ownership of 100 % in ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018 (the “Group”) when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o. Revenue and operating results Q2 The Group’s revenue amounted to SEK 10,993,693 (74,034) in the second quarter and resulted in an operating income of SEK 1,485,054 (-2,319,054). The majority of the operating expenses are related to procurement of raw materials and products, salaries, insurance expenses, legal services, audit services, and accounting services. The holding company, ODI Pharma AB, has generated revenues of SEK 2,568,466 (1,048,331) during the second quarter. Balance sheet and solidity ODI Pharma AB was registered with the Swedish Companies Registration Office on the 23rd of October 2019 with shareholder equity of SEK 500 000. The Company has no long-term liabilities. The group was established on the 28th of June 2018. Total assets of the Group amounted to SEK 9,933,520 (6,628,026) and consisted primarily of current receivables and cash and cash equivalents. The solidity of the Group was 19% (7%) at quarter-end. The holding company, ODI Pharma AB, stated total assets of SEK 5,762,101 (9,241,962) consisting primarily of receivables in group companies. The solidity of ODI Pharma AB was 25% (28%). Cash flow and investments Cash flow from operations in the Group during the second quarter amounted to SEK 1,984,285 (-1,560,867). Cash flow from financing and investment activities during the second quarter amounted to SEK 0 (1,896,969), resulting in cash flow from October 2025 to December 2025 of SEK 1,984,285 (335,829). The holding company, ODI Pharma AB, showed a cash flow for the period (after financing and investment activity) of SEK 249,640 (694,854) during the second quarter. The share The shares of ODI Pharma were listed on Spotlight Stock Market on the 23rd of January 2020. The short name/ticker is ODI and the ISIN code is SE0013409760. Spotlight Stock Market operates a so- called MTF platform under the supervision of the Swedish Financial Supervisory Authority. On the 31st of December 2025, the number of shares in ODI Pharma amounted to 18,348,419 (15,915,034). The average number of shares during the second quarter amounted to 18,348,419 (15,915,034). Every share equals the same rights to the Company´s assets and results.
Page 9
9 Warrants No warrants are outstanding to any party. Financial calendar January 2026 – March 2026 (Q3) 28 of May 2026 July 2025 – June 2026 (Year end report) 27 of August 2026 Shareholders The table below presents the current shareholders, as of 31st of December 2025, with more than 5 percent of the votes and capital in ODI Pharma AB. Auditor’s review The half-year report has not been reviewed by the Company’s auditor. Accounting policy of the quarterly report The financial statements of ODI Pharma AB, as well as the ODI Pharma Group, are prepared per the Swedish Annual Accounts Act and the standards of the Swedish Accounting Standards Board (BFNAR) 2012:1 (K3) and Spotlight Stock Market’s Rules and Regulations, as applicable. Consolidated accounts include parent company and subsidiaries in which the parent company directly or indirectly owns shares that are more than 50 % of the votes. Intangible and tangible assets are at the acquisition value reduced with accumulated depreciation according to plan and eventually write-downs. Depreciation is done linearly in relation to expected useful life. The financial overviews of ODI Pharma’s subsidiaries were prepared in the local currency (CHF for the Swiss subsidiary and PLN for the Polish subsidiary). For this report, the local currencies have been recalculated to SEK in the financial overview, based on data from Sveriges Riksbank on the 31st of December 2025, respectively the average exchange rate for the presented time frame. Common Control Transaction During the financial year 2019/2020, ODI Pharma AB acquired ODI Pharma Schweiz AG from the previous owners through a related party transaction. The acquisition was carried out through a promissory note of CHF 100,000, which, in accordance with an established agreement, was subject to set-off in connection with a new issue using the K3 currency conversion principle. K3 does not comment on common control transactions and in the absence of guidance, the company has chosen to report the transaction based on the former group's book values, since the newly formed company is not considered an acquirer in the transaction. This means that ODI Pharma Sweden AB's consolidated accounts are a continuation of what was previously reported in the ODI Pharma Switzerland Name Number of shares The proportion of votes and capital (%) Volker Wiederrich 7,044,909 38.43 Niclas Kappelin 5,320,112 29.02 Derek Simmross 4,257,692 23.23 Other shareholders (approx. 1,000) 1,707,706 9.32 Total 18,330,419 100.00
Page 10
10 Group and the comparative figures presented are the ODI Pharma Switzerland Group's financial information for 2018, adjusted for differences in accounting principles. Other operational risks and uncertainties The risks and uncertainties that ODI Pharma’s operations are exposed to are summaries related to factors such as development, competition, permissions, capital requirements, customers, suppliers/manufacturers, currencies, and interest rates. ODI Pharma’s operations require a solid cash and capital basis. The operations would face severe downside in case a solid basis is not sustained. Submission of the half-year report Stockholm, 26 of February 2026 ODI Pharma AB The Board of Directors For further information, please contact Volker Wiederrich, Chairman E-mail: info@odipharma.com Website: https://www.odipharma.com/
Page 11
11 ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018. Income statement – the group 2025-10-01 2024-10-01 2025-07-01 2024-07-01 2024-07-01 SEK 2025-12-31 2024-12-31 2025-12-31 2024-12-31 2025-06-30 3 months 3 months 6 months 6 months 12 months Revenue Net Sales 10,932,119 0 16,900,262 -4,965 3,133,879 Other operating income 61,574 74,034 91,090 181,434 314,947 10,993,693 74,034 16,991,352 176,469 3,448,826 Operating expenses Cost of goods sold -7,304,556 0 -11,774,895 0 -2,294,815 External expenses -1,352,909 -2,156,590 -2,284,324 -3,147,814 -4,717,315 Personal expenses -844,021 -151,314 -1,063,821 -516,807 -1,394,156 Depreciation and amortization -1,429 -497 -1,771 -997 -1,972 Other operating expenses -5,724 -84,686 -274,772 -91,173 -491,725 Operating cost -9,508,639 -2,393,088 -15,399,583 -3,756,791 -8,899,983 Operating income 1,485,054 -2,319,054 1,591,769 -3,580,322 -5,451,157 Profit/loss from financial items Other interest income and similar profit/loss items 10,154 34,956 13,243 65,411 263,051 Interest expense and similar profit/loss items -196,611 -278,422 -349,633 -438,379 -741,009 Income after financial items 1,298,597 -2,562,520 1,255,378 -3,953,290 -5,929,115 Income before taxes 1,298,597 -2,562,520 1,255,380 -3,953,290 -5,929,115 Taxes 0 0 -24 -24 -4,228 Net income 1,298,597 -2,562,520 1,255,356 -3,953,314 -5,933,343 Number of shares in the beginning of the period 18,330,419 15,220,000 18,348,419 15,220,000 15,220,000 Number of shares at the end of the period 18,330,419 15,220,000 18,348,419 15,915,034 18,330,419 Average number of shares 18,330,419 15,220,000 18,348,419 15,567,517 16,775,210 Earnings per share, SEK 0.07 -0.16 0.07 -0.25 -0.35
Page 12
12 Balance Sheet – the group SEK 2025-12-31 2024-12-31 2025-06-30 Assets Fixed assets Subscribed but unpaid capital - - 1,000,000 Tangible fixed assets Equipment, machines, tools 13,596 5,576 4,484 13,596 5,576 1,004,484 Total fixed assets 13,596 5,576 1,004,484 Current assets Inventories Raw materials and consumables - - - Finished goods and goods for resale - - - Advance payments to supplier - - - - - - Current receivables Trade receivables 4,237,391 133,736 115,582 Tax receivables - - 0 Other current receivables 803,947 953,083 1,3377,494 Prepaid expenses and accrued income 117,773 176,845 628,604 5,159,111 1,263,664 2,121,680 Cash and cash equivalents 4,760,813 5,358,786 1,484,040 Total current assets 9,919,924 6,622,450 3,605,720 TOTAL ASSETS 9,933,520 6,628,026 4,610,205
Page 13
13 Changes in equity – the group SEK 2025-12-31 2024-12-31 2025-06-30 EQUITY AND LIABILITIES Equity Share capital 733,216 608,800 733,216 Non-registered capital - - 96,615 Other contributed capital 27,076,016 24,079,796 25,957,080 Other equity including result for the period -25,874,583 -24,243,584 -26,265,652 Equity attributed to shareholders in parent company 1,934,650 445,012 424,644 Current liabilities Account payables 4,893,827 1,423,444 388,498 Tax liabilities - - 4,186 Other current liabilities 3,092,592 4,020,275 2,786,625 Accrued expenses and prepaid income 12,450 739,296 1,006,251 Total current liabilities 7,998,869 6,183,015 4,185,559 TOTAL EQUITY AND LIABILITIES 9,933,518 6,628,026 4,610,203
Page 14
14 Cash flow statement – the group 2025-10-01 2024-10-01 2025-07-01 2024-07-01 2024-07-01 SEK 2025-12-31 2024-12-31 2025-12-31 2024-12-31 2025-06-30 3 months 3 months 6 months 6 months 12 months Operating activities Net operating profit/loss 1,496,459 -1,974,715 1,588,556 -3,226,089 -5,451,157 Non-cash affecting share issue - - 1,001,700 Adjustment for non-cash flow items Depreciations and write-downs 1,448 498 1,795 997 1,963 Current exchange differences -23,684 44,450 -23,585 14,805 -23,585 Other items not affecting cash flow - - - - 1,001,700 Cash flow from operating activities 1,474,223 -1,929,767 1,566,766 -3,210,287 -4,471,079 Received interest 1,370 27,088 1,589 30,133 30,934 Paid interest -186,647 -273,245 -331,011 -417,018 -680,562 Paid tax - 80,132 -4,248 93,348 92,838 Cash flow from operation before change in working capital 1,288,946 -2,095,792 1,233,096 -3,503,824 -5,027,869 Cash flow from change in working capital Change in inventories and ongoing works - - - - - Increase (-) Decrease (+) of operating receivables -1,135,156 -898,664 -3,524,018 8,251,707 9,978,197 Increase (+) Decrease (-) of operating liabilities 1,830,494 1,433,588 5,727,556 -3,931,976 -8,256,172 Total change in working capital 695,339 534,925 2,203,538 4,319,731 1,722,025 Cash flow from operating activities 1,984,285 -1,560,867 3,436,634 815,907 -3,305,844 Investment activities Investments in tangible fixed assets - - - - - Cash flow from investment activities - - - - - Financing activities Long-term borrowings - - - - - New share issue - 2,238,009 - 2,238,009 2,238,009 New share issue expenses - -341,313 - -341,313 - Cash flow from financing activities - 1,896,696 - 1,896,696 2,238,009 Cash flow for the period 1,984,285 335,829 - 2,712,603 -1,067,835 Cash and cash equivalents at beginning of year 2,869,757 4,911,645 1,513,688 2,665,385 2,643,931 Effects of exchange rate changes on cash -93,229 111,312 -189,509 -19,202 -92,056 Cash and cash equivalents at end of year 4,760,813 5,358,786 4,760,813 5,358,786 1,484,039
Page 15
15 Income statement – ODI Pharma AB 2025-10-01 2024-10-01 2025-07-01 2024-07-01 2024-07-01 SEK 2025-12-31 2024-12-31 2025-12-31 2024-12-31 2025-06-30 3 months 3 months 6 months 6 months 12 months Revenue Net sales 2,557,858 976,330 4,128,346 2,842,923 1,320,556 Other operating income 10,608 72,001 36,817 75,179 197,226 2,568,466 1,048,331 4,165,163 2,918,102 1,517,782 Operating expenses Cost of goods sold 0 0 - - - External expenses -1,098,201 -1,845,343 -1,817,383 -1,997,182 -3,249,163 Personal expenses -808,599 -113,032 -1,028,399 -477,487 -1,355,433 Depreciation and amortisation - - - - - Other operating expenses -6,609 -105,472 -179,042 -122,144 -472,388 Total operating cost -1,913,409 -2,063,847 -3,024,824 -2,596,813 -5,076,983 Operating income 655,057 -1,015,516 1,140,339 321,289 -3,559,201 Income from financial items Anticipated dividend - - - - - Other interest income and similar profit/loss items 1,370 29,994 1,589 30,133 195,884 Interest expense and similar profit/loss items -183,906 -273,743 -334,562 -411,542 -672,840 Income after financial items 472,521 -1,259,265 807,366 -60,120 -4,036,158 Income before taxes 472,521 -1,259,265 807,366 -60,120 -4,036,158 Taxes - - - - - Net income 472,521 -1,259,265 807,366 -60,120 -4,036,158 Number of shares in the beginning of the period 18,348,419 15,220,000 18,348,419 15,220,000 15,220,000 Number of shares at the end of the period 18,348,419 15,915,034 18,348,419 15,915,034 18,330,419 Average number of shares 18,348,419 15,567,517 18,348,419 15,567,517 16,775,210 Earnings per share, SEK 0.03 -0.08 0.04 0.00 -0.24
Page 16
16 Balance Sheet – ODI Pharma AB SEK 2025-12-31 2024-12-31 2025-06-30 ASSETS Fixed assets Subscribed but unpaid capital - - 1,000,000 Financial fixed assets Loan group companies - - - Participations in groups companies 967,200 967,200 967,200 967,200 967,200 1,967,200 Total fixed assets 967,200 967,200 1,967,200 Current assets Inventories Raw materials and consumables - - - Finished goods and goods for resale - - - Advance payments to suppliers - - - - - - Current receivables Trade receivables - - - Receivables in group companies 2,950,396 4,210,050 1,370,386 Other current receivables 710,691 812,676 1,259,295 Prepaid expenses and accrued income - - 252,924 3,661,087 5,022,726 2,882,605 Cash and cash equivalents 1,133,814 3,252,036 210,158 Total current assets 4,794,901 8,274,762 3,092,763 TOTAL ASSETS 5,762,101 9,241,962 5,059,963
Page 17
17 Changes in equity – ODI Pharma AB SEK 2025-12-31 2024-12-31 2025-06-30 EQUITY AND LIABILITIES Equity Restricted reserves Share capital 733,216 608,800 636,601 Non-registered capital - - 96,615 Non-restricted reserves Share premium reserve Share premium 25,587,560 23,710,276 25,587,560 Retained earnings -25,711,115 -21,674,958 -21,674,958 Profit or loss for period 807,365 -60,121 -4,036,157 Total equity 1,417,026 2,583,997 609,661 Current liabilities Account payables 944,307 1,170,466 239,855 Liabilities to group companies 621,760 730,327 720,627 Other current liabilities 2,786,625 4,020,275 2,786,625 Accrued expenses and prepaid income -7,619 736,898 703,195 Total current liabilities 4,345,073 6,657,966 4,450,302 TOTAL EQUITY AND LIABILITIES 5,762,099 9,241,963 5,059,963
Page 18
18 Cash flow statement – ODI PHARMA AB SEK 2025-10-01 2024-10-01 2025-07-01 2024-07-01 2024-07-01 2025-12-31 2024-12-31 2025-12-31 2024-12-31 2025-06-30 3 months 3 months 6 months 6 months 12 months Operating activities Net operating profit/loss 655,057 -674,204 1,140,339 662,600 -3,559,201 Non-cash affecting share issue - - - - 1,001,700 Adjustment for non-cash flow items Depreciations and write-downs - - - - - Current exchange differences - 44,450 - 44,450 - Other items not affecting cash flow - - - - 1,001,700 Cash flow from operating activities 655,057 -629,754 1,140,339 707,050 -2,557,501 Received interest 1,370 29,993 1,589 30,133 30,934 Paid interest -183,906 -273,743 -326,164 -411,542 -672,840 Paid tax - - - - 0 Cash flow before change in working capital 472,521 -873,504 815,764 325,641 -3,199,407 Cash flow from change in working capital Change in inventories and ongoing works - - - - - Increase (-) Decrease (+) of operating receivables -602,458 -991,277 221,518 -1,555,782 1,036,654 Increase (+) Decrease (-) of operating liabilities 379,577 662,939 -105,229 425,112 -1,965,906 Total change in working capital -222,881 -328,338 116,289 -1,130,670 -929,252 Cash flow from operating activities 249,640 -1,201,842 932,053 -805,029 -4,128,659 Investment activities Investments - - - - - Cash flow from investment activities - - - - - Investing activities Loan - - - - - Cash flow from investing activities - - - - - Financing activities Long-term borrowings - - - 224,510 - Anticipated dividend - - - - - New shares issue 2,238,009 - 2,238,009 2,238,009 New share issue expenses - -341,313 - -241,313 - Cash flow from financing activities - 1,896,696 - 2,121,206 2,238,009 Cash flow for the period 249,640 694,854 932,053 1,316,177 -1,890,650 Cash and cash equivalents at the beginning of year 884,254 2,557,182 210,158 1,935858 1,935,858 Effects of exchange rate changes on cash -78 - -8,398 - 164,950 Cash and cash equivalents at the end of year 1,133,814 3,252,036 1,133,814 3,252,036 210,158
Page 19
19